Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis

doi:10.1186/s12933-023-02035-8

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34793

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34793

標題:	Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
作者:	Chen, Jui-Yi Pan, Heng-Chih Shiao, Chih-Chung Chuang, Min-Hsiang See, Chun Yin Yeh, Tzu-Hsuan Yang, Yafei Chu, Wen-Kai Wu, Vin-Cent
貢獻者:	Chi Mei Med Ctr, Dept Internal Med, Div Nephrol Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Keelung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol Chang Gung Univ, Coll Med Natl Taiwan Univ, Grad Inst Clin Med, Coll Med Keelung Chang Gung Mem Hosp, Community Med Res Ctr Camillian St Marys Hosp Luodong, Dept Internal Med, Div Nephrol St Marys Jr Coll Med Nursing & Management Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med ,Div Nephrol Everan Hosp, Dept Internal Med, Div Nephrol Natl Taiwan Univ Hosp, Dept Internal Med Natl Taiwan Univ Hosp, NSARF, Study Grp ARF Taiwan Primary Aldosteronism Investigators
關鍵字:	SGLT2 inhibitor Diabetes Heart failure Chronic kidney disease Network meta-analysis
日期:	2023
上傳時間:	2024-12-25 11:03:33 (UTC+8)
出版者:	BMC
摘要:	BackgroundA comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF), and chronic kidney disease (CKD) has not been previously conducted.MethodsWe searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk ratios (RRs). Risk of Bias tool 2.0 was used to assess bias, and CINeMA to assess the certainty of evidence. In the subgroup analysis, the SGLT2 inhibitors were classified into highly (dapagliflozin, empagliflozin, and ertugliflozin) and less selective SGLT2 inhibitors (canagliflozin and sotagliflozin).ResultsA total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin users had a significantly lower risk of all-cause death compared to dapagliflozin users in DM population (RR: 0.81, 95% CI 0.69-0.96). In HF population, sotagliflozin users had a borderline significantly lower risk of CV death or hospitalization for HF (HHF) than dapagliflozin users (RR: 0.90, 95% CI 0.80-1.01). In non-HF population, those who used canagliflozin had a significantly lower risk of CV death or HHF compared with those who used dapagliflozin (RR: 0.75, 95% CI 0.58-0.98). At last, for HF patients, those who used less selective SGLT2 inhibitors had a significantly lower risk of MACEs compared to those who used highly selective SGLT2 inhibitors (RR: 0.75, 95% CI 0.62-0.90).ConclusionsOur network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrated a reduced risk of cardiovascular death or HHF compared to dapagliflozin users in those without HF. In HF patients, less selective SGLT2 inhibitors showed superior CV composite outcomes, even surpassing the performance of highly selective SGLT2 inhibitors.Trial registration: PROSPERO [CRD42022361906].ConclusionsOur network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrated a reduced risk of cardiovascular death or HHF compared to dapagliflozin users in those without HF. In HF patients, less selective SGLT2 inhibitors showed superior CV composite outcomes, even surpassing the performance of highly selective SGLT2 inhibitors.Trial registration: PROSPERO [CRD42022361906].
關聯:	Cardiovascular Diabetology, v.22, n.1, Article 290
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	37	检视/开启
s12933-023-02035-8.pdf		2079Kb	Adobe PDF	14	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....